Repositorio Dspace

Risk of new primary cancer, locoregional progression or metastasis associated with bDMARDs and tsDMARDs in patients with rheumatoid arthritis and prior cancer: insights from the ARCA registry

Mostrar el registro sencillo del ítem

dc.contributor.author Molina-Collada, Juan
dc.contributor.author Plasencia-Rodríguez, Chamaida
dc.contributor.author García-García, Veronica
dc.contributor.author Del-Bosque, Ivan
dc.contributor.author Pavia-Pascual, Marina
dc.contributor.author Villapun-Burgoa, Beatriz
dc.contributor.author Bourgeois-Avella, Camille
dc.contributor.author Roig-Kim, Montserrat
dc.contributor.author Narvaez, Javier
dc.contributor.author Hernández-Rodríguez, Isabel
dc.contributor.author Saez, Juan-Carlos
dc.contributor.author Almeida, Cristina
dc.contributor.author García-Dorta, Alicia
dc.contributor.author Uriarte-Itzazelaia, Esther
dc.contributor.author Campos, Daniel
dc.contributor.author Dos-Santos, Raquel
dc.contributor.author Pérez-Pampin, Eva
dc.contributor.author Jiménez-Nunez, Francisco-Gabriel
dc.contributor.author Fernández-Fernández, Elisa
dc.contributor.author Villalba, Alejandro
dc.contributor.author Bou, Nuria
dc.contributor.author Pérez-García, Carolina
dc.contributor.author Rusinovich-Lovgach, Olga
dc.contributor.author Martínez-Rodado, Alejandro
dc.contributor.author González, Roxana
dc.contributor.author Cepas-Gutiérrez, Francisco-José
dc.contributor.author Olivas-Vergara, Otto
dc.contributor.author Berrocal, Minerva
dc.contributor.author Molina, Nuria
dc.contributor.author González-Mazon, Inigo
dc.contributor.author Toledano, Esther
dc.contributor.author Tortosa-Cabanas, Marina
dc.contributor.author Vellosillo-González, Perceval
dc.contributor.author González-Navarro, Pablo
dc.contributor.author Navarro-Compan, Victoria
dc.contributor.author Carmona, Loreto
dc.date.accessioned 2026-11-11T09:05:30Z
dc.date.available 2026-11-11T09:05:30Z
dc.date.issued 2026-07
dc.identifier.citation Molina-Collada J, Plasencia-Rodriguez C, García-García V, Del Bosque I, Pavía-Pascual M, Villapún Burgoa B, et al. Risk of new primary cancer, locoregional progression or metastasis associated with bDMARDs and tsDMARDs in patients with rheumatoid arthritis and prior cancer: insights from the ARCA registry. RMD Open. julio de 2026;12(3):e007113. doi:10.1136/rmdopen-2026-007113
dc.identifier.issn 2056-5933
dc.identifier.uri https://sms.carm.es/ricsmur/handle/123456789/29171
dc.description.abstract OBJECTIVES: To compare the risk of new primary cancer, locoregional progression or metastasis across different disease-modifying antirheumatic drugs (DMARDs) strategies in real-world patients with rheumatoid arthritis (RA) and prior cancer. METHODS: The ARthritis and CAncer registry is a nationwide retrospective study, including patients with RA and prior cancer. Collected variables included RA characteristics, DMARDs received, cancer type and demographics. The primary outcome was the occurrence of new primary cancer, locoregional progression or metastasis during follow-up. Adjusted Cox regression models were used to estimate HRs for cancer events. Treatment strategies involving conventional synthetic (cs)DMARDs served as the reference for comparison. RESULTS: Among 728 patients with RA, 80 cases of cancer were identified over a cumulative exposure period of 11 022 years, with an overall cancer incidence rate of 7.3 (95% CI 5.8 to 9.0) per 1000 person-years. Adjusted HRs for all cancers (95% CI) compared with csDMARDs were 0.94 (0.73 to 1.21) for tumour necrosis factor inhibitors, 1.03 (0.61 to 1.74) for IL6-inhibitors, 0.81 (0.46 to 1.42) for CD20 inhibitors, 0.6 (0.26 to 1.4) for targeted synthetic DMARDs and 0.74 (0.41 to 1.34) for cytotoxic T-lymphocyte-associated protein 4-analogue. No differences in cancer risk were observed after adjusting for duration of exposure, line of advanced therapy or prior cancer status. CONCLUSION: This real-world data did not identify differences in the risk of new primary cancer, locoregional progression or metastasis across different DMARDs strategies in patients with RA and prior cancer.
dc.language.iso eng
dc.publisher BMJ PUBLISHING GROUP
dc.rights Atribución/Reconocimiento-NoComercial 4.0 Internacional
dc.rights.uri https://creativecommons.org/licenses/by-nc/4.0/deed.es *
dc.subject.mesh Humans
dc.subject.mesh Arthritis, Rheumatoid/drug therapy/complications/epidemiology
dc.subject.mesh Female
dc.subject.mesh Antirheumatic Agents/therapeutic use/adverse effects
dc.subject.mesh Registries
dc.subject.mesh Male
dc.subject.mesh Disease Progression
dc.subject.mesh Middle Aged
dc.subject.mesh Neoplasms/epidemiology/etiology/pathology
dc.subject.mesh Aged
dc.subject.mesh Retrospective Studies
dc.subject.mesh Incidence
dc.subject.mesh Risk Factors
dc.subject.mesh Neoplasm Metastasis
dc.subject.mesh Risk Assessment
dc.title Risk of new primary cancer, locoregional progression or metastasis associated with bDMARDs and tsDMARDs in patients with rheumatoid arthritis and prior cancer: insights from the ARCA registry
dc.type info:eu-repo/semantics/article
dc.identifier.pmid 42791026
dc.relation.publisherversion https://rmdopen.bmj.com/lookup/doi/10.1136/rmdopen-2026-007113
dc.type.version info:eu-repo/semantics/publishedVersion
dc.identifier.doi 10.1136/rmdopen-2026-007113
dc.journal.title Rmd Open


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución/Reconocimiento-NoComercial 4.0 Internacional Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución/Reconocimiento-NoComercial 4.0 Internacional

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta